Inhibitex, Inc.
(Public, NASDAQ:INHX) Watch this stockFind more results for
INHX:NASDAQ
Advertisement
Events
Nov 17, 2009
Lazard Capital Healthcare Conference
Nov 6, 2009
Q3 2009 Earnings Conference Call
Nov 6, 2009
Q3 2009 Earnings Release
|
More events from AOL Finance »
|
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | -1552.08% | -417.81% |
| Operating margin | -1558.33% | -459.49% |
| EBITD margin | - | -428.83% |
| Return on average assets | -69.89% | -29.19% |
| Return on average equity | -89.51% | -36.24% |
| Employees | 34 | - |
Address
Website links
Company website:
http://www.inhibitex.com
http://www.inhibitex.com
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Inhibitex, Inc. discussions
View all discussions »Description
Inhibitex, Inc. is a biopharmaceutical company focused on the development of differentiated anti-infective products to prevent and treat serious infections. The Company focuses in the development of small molecule antiviral compounds, and in particular, therapies to treat shingles (herpes zoster) and chronic hepatitis C infections (HCV). The Company’s anti-infective product candidates include FV-100, HCV Polymerase Inhibitors, HIV Integrase Inhibitors, Aurexis and Staphylococcal Vaccines.
Officers and directors
| Michael A. Henos | Chairman of the Board | |
| Russell H. Plumb | President, Chief Executive Officer, Chief Financial Officer, Director | |
| Joseph M. Patti Ph.D. | Chief Scientific Officer, Senior Vice President - Research and Development | |
| Geoffrey W. Henson Ph.D. | Senior Vice President - Drug Development | |
| M. James Barrett Ph.D. | Director | |
| Russell M. Medford M.D., Ph.D. | Director | |
| Marc L. Preminger | Director | |
| A. Keith Willard | Director | |
| Gabriele M. Cerrone | Director |